Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| 1 |
Linde
LIN
|
+$588M |
| 2 |
Apple
AAPL
|
+$574M |
| 3 |
Illumina
ILMN
|
+$398M |
| 4 |
argenx
ARGX
|
+$306M |
| 5 |
CTLT
CATALENT, INC.
CTLT
|
+$250M |
Top Sells
| 1 |
Meta Platforms (Facebook)
META
|
+$600M |
| 2 |
AbbVie
ABBV
|
+$323M |
| 3 |
Sherwin-Williams
SHW
|
+$309M |
| 4 |
Atlassian
TEAM
|
+$250M |
| 5 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$241M |
Sector Composition
| 1 | Technology | 31.85% |
| 2 | Healthcare | 19.69% |
| 3 | Industrials | 10.43% |
| 4 | Financials | 10.02% |
| 5 | Consumer Discretionary | 9.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1826
Standex International
SXI
$2.5B
| $703K | ﹤0.01% |
+5,746
| New | +$703K |
|
1827
UGI
UGI
$7.41B
| $702K | ﹤0.01% |
20,188
+15
| +0.1% | +$521 |
|
1828
Clover Health Investments
CLOV
$1.56B
| $700K | ﹤0.01% |
828,279
+764,436
| +1,197% | +$646K |
|
1829
Cannae Holdings
CNNE
$1.11B
| $699K | ﹤0.01% |
34,667
+17,957
| +107% | +$362K |
|
1830
Orion
OEC
$572M
| $699K | ﹤0.01% |
26,780
+14,873
| +125% | +$388K |
|
|
PPYA
1831
DELISTED
Papaya Growth Opportunity Corp. I Class A Common Stock
PPYA
| $697K | ﹤0.01% |
67,000
-186
| -0.3% | -$1.93K |
|
1832
Victory Capital Holdings
VCTR
$4.74B
| $695K | ﹤0.01% |
23,748
+10,005
| +73% | +$293K |
|
1833
Revolve Group
RVLV
$1.72B
| $695K | ﹤0.01% |
26,423
+11,158
| +73% | +$293K |
|
1834
Hilltop Holdings
HTH
$2.2B
| $694K | ﹤0.01% |
23,423
+12,401
| +113% | +$368K |
|
1835
Teva Pharmaceuticals
TEVA
$22.7B
| $694K | ﹤0.01% |
78,510
| – | – |
|
|
VGR
1836
DELISTED
Vector Group Ltd.
VGR
| $694K | ﹤0.01% |
57,817
+31,334
| +118% | +$376K |
|
1837
Roku
ROKU
$14.1B
| $692K | ﹤0.01% |
10,520
-3,980
| -27% | -$262K |
|
1838
Knowles
KN
$1.89B
| $689K | ﹤0.01% |
40,536
+21,911
| +118% | +$372K |
|
1839
Cinemark Holdings
CNK
$3.17B
| $688K | ﹤0.01% |
46,511
+26,056
| +127% | +$385K |
|
1840
Veracyte
VCYT
$2.53B
| $686K | ﹤0.01% |
30,784
+17,151
| +126% | +$382K |
|
1841
Appian
APPN
$2.31B
| $684K | ﹤0.01% |
15,423
+8,266
| +115% | +$367K |
|
1842
Astrana Health
ASTH
$1.38B
| $684K | ﹤0.01% |
+18,774
| New | +$684K |
|
1843
Agios Pharmaceuticals
AGIO
$2.1B
| $681K | ﹤0.01% |
29,647
+21,058
| +245% | +$483K |
|
1844
Huron Consulting
HURN
$2.41B
| $680K | ﹤0.01% |
8,455
+4,942
| +141% | +$398K |
|
1845
Xencor
XNCR
$621M
| $679K | ﹤0.01% |
24,370
+13,732
| +129% | +$383K |
|
1846
HighPeak Energy
HPK
$909M
| $676K | ﹤0.01% |
29,393
-17,880
| -38% | -$411K |
|
|
BYNO
1847
DELISTED
byNordic Acquisition Corporation Class A Common Stock
BYNO
| $676K | ﹤0.01% |
65,000
| – | – |
|
1848
International Seaways
INSW
$2.28B
| $676K | ﹤0.01% |
16,216
+8,894
| +121% | +$371K |
|
1849
CTS Corp
CTS
$1.23B
| $675K | ﹤0.01% |
13,654
+7,727
| +130% | +$382K |
|
1850
Malibu Boats
MBUU
$623M
| $674K | ﹤0.01% |
11,950
+3,497
| +41% | +$197K |
|